Registry for double lung transplants in patients with lung-limited cancers
Official title: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies (DREAM) - a Prospective Observational Registry Study for Patients Undergoing Lung Transplantation for Medically Refractory Cancers Confined to the Lungs
Run by Northwestern University · NCT05671887 · Data updated 2026-11-12
This study is collecting information on patients with lung-limited cancers who are getting double lung transplants to see how well the procedure works for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 125 (estimated) |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | November 16, 2022 |
| Main results expected | November 2032 |
| Study ends | November 2032 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT05671887 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults up to 80 years old with refractory lung cancer or lung-limited metastasis and no extrapulmonary disease.
✕Probably not a fit
Patients with extrapulmonary disease or those who do not meet the eligibility criteria for lung transplantation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry aims to collect data on patients undergoing double lung transplantation specifically for lung-limited malignancies that do not have extrapulmonary disease. The study will track outcomes and survival rates in this unique patient population, which has historically been underrepresented in lung transplant procedures. By focusing on patients with refractory lung cancer and those with lung-limited metastasis, the registry seeks to provide insights into the efficacy and safety of lung transplantation as a treatment option. Participants will be evaluated based on strict eligibility criteria to ensure they are suitable candidates for the procedure.
Why it matters
Potential benefit: If successful, this registry could improve treatment options and outcomes for patients with lung-limited cancers requiring transplantation.
How similar studies have gone: While lung transplantation for cancer is uncommon, there have been successful reports in similar cases, indicating potential for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Any patient who is undergoing double lung transplantation as part of the clinical program, consents for this prospective observational trial, and has one of the following conditions will be eligible. * Common Inclusion Criteria * Adults of Age ≦ 80 * Resistant or refractory to or without available standard of care treatment options or experimental treatment options that are known to increase survival outcome * Patients without any extrapulmonary disease * Patients with good general health with an ability to withstand physiologic stressors and undergo psychosocial evaluation by the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) or other assessment tools * Patients to meet all other criteria for lung transplantation including insurance approval and United Network for Organ Sharing (UNOS) registration Inclusion Criteria for Cohort A * Histologically confirmed selected lung non-small cell lung cancer including but not limited to: o according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification \- Lepidic dominant pattern * Adenocarcinoma in situ * Minimally invasive adenocarcinoma * Non mucinous lepidic predominant invasive adenocarcinoma o based on 2015 World Health Organization (WHO) classification of lung tumors including \- Invasive mucinous adenocarcinoma * Mixed invasive mucinous and mucinous adenocarcinoma * Colloid adenocarcinoma * Enteric adenocarcinoma * Minimally invasive adenocarcinoma * Nonmucinous * Mucinous \- Preinvasive lesions * Atypical adenomatous hyperplasia * Adenocarcinoma in situ * Nonmucinous * Mucinous * based on the 2004 WHO classification of lung tumors including - Bronchioloalveolar carcinoma * Nonmucinous * Mucinous * Mixed nonmucinous and mucinous or indeterminate * Without any distant metastasis confirmed by standard staging work-up * Without brain metastasis confirmed by brain imaging * Without unidentified primary site of cancer Inclusion Criteria for Cohort B * Metastatic cancers to lung alone - including but not limited to germ cell tumors, head \& neck tumors, colorectal tumors, renal cell tumors, testicular cancer * Without any other distant metastasis confirmed by standard staging work-up Inclusion Criteria for Cohort C * Respiratory failure with a history of cancer in the last 5 years - including, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH) * Without any other distant metastasis confirmed by standard staging work-up Exclusion Criteria: * Exclusion criteria * Adults unable or unwilling to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Vulnerable Populations * Presence of extrapulmonary disease or mediastinal nodal disease at the time of transplant referral * Small Cell Cancers * Unidentified primary site of cancer for Cohort A * Progression of disease or confirmed distant metastases or mediastinal nodal disease at any point during transplantation work-up * Medical ineligibility for lung transplantation after multidisciplinary assessment * Not a suitable candidate according to the lung transplantation protocol for treatment of lung confined primary or metastatic tumors * Body mass index more than 35 kg/m2 * Evidence of co-existing malignancies for Cohort A * Untreatable significant dysfunction of another major organ system including heart, liver, kidney, or brain unless combined organ transplantation can be performed * Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and/or coronary artery disease not amenable to revascularization * Uncorrectable bleeding diathesis * Evidence of active Mycobacterium tuberculosis infection * Significant chest wall or spinal deformity expected to cause severe restriction after transplantation
Where it's running
-
Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital)
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Young Chae, MD MPH MBA — Northwestern University
- Study coordinator: Lung Transplant Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital)
- Email: anne.oboye@nm.org
- Phone: 312-695-5864
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Research on improving outcomes for lung transplant donors and recipients
This study is trying to see how different donor and medical practices affect the health of lung transplant patients and donors, while also looking for blood markers that might predict complications after the surgery.
-
Registry for thoracic disease specimens
This study is collecting samples from patients with lung diseases like lung cancer to help researchers learn more about these conditions and find better treatments.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
Multidisciplinary non-drug program to improve quality of life after solid organ transplant
A multidisciplinary, non-drug program using acupuncture, remote physical rehab, and brain-health activities is being tested to see if it can improve quality of life for adults at least one year after heart, kidney, liver, or lung transplant.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.